Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)

Next Previous
Trial Profile

A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imlifidase (Primary) ; Cyclophosphamide; Glucocorticoids
  • Indications Anti-glomerular basement membrane disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GOOD-IDES-02
  • Sponsors Hansa Biopharma AB

Most Recent Events

  • 06 Feb 2025 According to a Hansa Biopharma AB media release, data read out is expected in the second half of 2025.
  • 06 Dec 2024 Status changed from recruiting to active, no longer recruiting.
  • 05 Dec 2024 According to a Hansa Biopharma AB media release, the company expects sharing further updates on the outcome of the study and potential path forward in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top